RVL Pharmaceuticals plc Provides Business Update
05 Julho 2023 - 7:50AM
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a
specialty pharmaceutical company organized in Ireland focused on
the commercialization of UPNEEQ® (oxymetazoline hydrochloride
ophthalmic solution), 0.1%, for the treatment of acquired
blepharoptosis, or droopy or low-lying eyelids, in adults, today
announced that, as authorized by the Board of Directors, the
Company has been considering certain strategic alternatives. These
include discussions to acquire a specific potential counterparty in
an all stock strategic transaction and discussions with potential
financing sources regarding incremental funding for the combined
company in the event such a transaction is consummated. This
strategic transaction, if consummated, would result in a more
diversified aesthetics company with meaningful revenue and
synergies. In addition, the Company is in business development
discussions with other parties to further enhance the business on a
go-forward basis.
There is no certainty that the Company will
enter into a strategic transaction or that any financing will be
consummated. Further announcements will be made as and when
appropriate.
Forward-Looking Statements
This press release includes statements that
express the Company’s opinions, expectations, beliefs, plans,
objectives, assumptions or projections regarding future events or
future results and therefore are, or may be deemed to be,
“forward-looking statements.” The Company’s actual results may vary
significantly from the results anticipated in these forward-looking
statements, which can generally be identified by the use of
forward-looking terminology, including the terms “believes,”
“expects,” “may,” “will,” “should,” “seeks,” “projects,”
“approximately,” “intends,” “plans,” “targets,” “estimates” or
“anticipates,” or, in each case, their negatives or other
variations or comparable terminology. These forward-looking
statements include all matters that are not historical facts. They
include statements regarding the Company’s intentions, beliefs or
current expectations concerning, among other things, its
discussions with a potential counterparty to a strategic
transaction and financing sources. By their nature, forward-looking
statements involve risks and uncertainties because they relate to
events and depend on circumstances that may or may not occur in the
future. We may not achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not
place significant reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make. In particular, discussions with the potential
counterparty to a transaction, as well as potential financing
sources, may terminate for any or no reason and anticipated
synergies may not be realized. Additional important factors that
could cause actual results and events to differ materially from
those indicated in the forward-looking statements include the
following: UPNEEQ’s ability to reach market acceptance by
clinicians and patients; our ability to successfully commercialize
UPNEEQ; our customers’ willingness to pay the price we charge for
UPNEEQ; the results of our marketing and sales expenditures; our
dependence on third-party suppliers and distributors for UPNEEQ;
UPNEEQ’s ability to produce its intended effects; failures of or
delays in clinical trials or other delays in obtaining regulatory
approval or commencing product sales for new products; the impact
of legal proceedings; and other risks and uncertainties more fully
described in the “Risk Factors” section of our Annual Report on
Form 10-K filed on March 20, 2023, and other filings that the
Company makes with the Securities and Exchange Commission. These
forward-looking statements speak only as of the time of this press
release and we do not undertake to publicly update or revise them,
whether as a result of new information, future events or otherwise,
except as required by law.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty
pharmaceutical company focused on the commercialization of UPNEEQ®
(oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the
treatment of acquired blepharoptosis, or low-lying eyelid, in
adults. UPNEEQ is the first non-surgical treatment option approved
by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals
plc
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
RVL Pharmaceuticals (NASDAQ:RVLP)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
RVL Pharmaceuticals (NASDAQ:RVLP)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024